2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions

View by Date

Saturday, October 6, 2018

1:45pm-3:15pm: Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

V. Pitz, N. Malek, K. Grosset, D. Grosset (Glasgow, United Kingdom)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: VIT-D and Tics Movement Disorder

N. Gemawat (Mumbai, India)

Pediatric Movement Disorders · Hall 3FG

1:45pm-3:15pm: Vitamin B3 and Neurodevelopment in Parkinson’s Disease

A. Williams, S. Griffin, R. Fricker (Birmingham, United Kingdom)

Therapy in Movement Disorders: Gene and Cell-Based Therapies · Hall 3FG

1:45pm-3:15pm: VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial

P. Larson, K. Bankiewicz, A. Van Laar, R. Richardson, B. Ravina, A. Kells, B. Boot, A. Martin, M. Thompson, C. Christine (San Francisco, CA, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Weight loss and nutritional status in Parkinson’s disease patients under levodopa/carbidopa intestinal gel infusion treatment

M. Fabbri, M. Zibetti, L. Beccaria, A. Romagnolo, E. Montanaro, J. Ferreira, L. Lopiano (Lisbon, Portugal)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Weight loss in STN DBS in Parkinson’s Disease? Long-term outcome of a prospective cohort at 5 years

D. Chan, C. Chan, A. Chan, C. Lau, C. Zhu, W. Poon, V. Mok (Hong Kong, Hong Kong)

Surgical Therapy: Parkinson's Disease · Hall 3FG

1:45pm-3:15pm: Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion

B. Fernández-Rodríguez, J. Dupouy, E. Harroch, MH. Fabre-Delcros, C. Barthélémy, P. Loubière, K. Barange, C. Brefel-Courbon, O. Rascol, F. Ory-Magne (Toulouse, France)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: What is the relationship between dyskinesia and performance of activities of daily living in patients with Parkinson’s disease?

E. Goubault, S. Bogard, K. Lebel, C. Duval (Montreal, QC, Canada)

Drug-Induced Movement Disorders · Hall 3FG

1:45pm-3:15pm: What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years

T. Dominey, S. Buff, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture

J. Ferrario, A. Bernardi, P. Ballestero, M. Ferrario, M. Schenk, E. Avale, S. Guerrero, O. Gershanik (Buenos Aires, Argentina)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG